Celltrion Eyes Near-Term Omalizumab Opportunity With CHMP Backing
Korean Firm’s Omlyclo Biosimilar To Xolair First Recommended For EU Approval
The pool of prospective Xolair biosimilars is small, with only Teva and Kashiv BioSciences/Alvotech disclosing Phase III comparison trials for their biosimilar products. Ahead of them in the pack, Celltrion has just taken a giant stride towards the first pan-European marketing approval.
